- Home
- SPNT vs BLTE Comparison
SPNT vs BLTE Comparison
Compare SPNT & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNT
- BLTE
- Stock Information
- Founded
- SPNT 2011
- BLTE 2018
- Country
- SPNT Bermuda
- BLTE United States
- Employees
- SPNT N/A
- BLTE N/A
- Industry
- SPNT Property-Casualty Insurers
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- SPNT Finance
- BLTE Health Care
- Exchange
- SPNT Nasdaq
- BLTE Nasdaq
- Market Cap
- SPNT 2.3B
- BLTE 2.1B
- IPO Year
- SPNT N/A
- BLTE 2022
- Fundamental
- Price
- SPNT $17.30
- BLTE $66.22
- Analyst Decision
- SPNT
- BLTE Strong Buy
- Analyst Count
- SPNT 0
- BLTE 4
- Target Price
- SPNT N/A
- BLTE $96.67
- AVG Volume (30 Days)
- SPNT 728.7K
- BLTE 48.2K
- Earning Date
- SPNT 04-29-2025
- BLTE 03-17-2025
- Dividend Yield
- SPNT N/A
- BLTE N/A
- EPS Growth
- SPNT N/A
- BLTE N/A
- EPS
- SPNT 1.04
- BLTE N/A
- Revenue
- SPNT $2,656,400,000.00
- BLTE N/A
- Revenue This Year
- SPNT N/A
- BLTE N/A
- Revenue Next Year
- SPNT N/A
- BLTE N/A
- P/E Ratio
- SPNT $16.40
- BLTE N/A
- Revenue Growth
- SPNT N/A
- BLTE N/A
- 52 Week Low
- SPNT $11.49
- BLTE $31.01
- 52 Week High
- SPNT $17.62
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- SPNT 78.39
- BLTE 56.99
- Support Level
- SPNT $14.34
- BLTE $64.69
- Resistance Level
- SPNT $15.05
- BLTE $67.40
- Average True Range (ATR)
- SPNT 0.43
- BLTE 2.11
- MACD
- SPNT 0.21
- BLTE -0.37
- Stochastic Oscillator
- SPNT 90.24
- BLTE 30.77
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.